Cargando…
IKBKE activity enhances AR levels in advanced prostate cancer via modulation of the Hippo pathway
Resistance to androgen receptor (AR) targeting therapeutics in prostate cancer (PC) is a significant clinical problem. Mechanisms by which this is accomplished include AR amplification and expression of AR splice variants, demonstrating that AR remains a key therapeutic target in advanced disease. F...
Autores principales: | Bainbridge, Alex, Walker, Scott, Smith, Joseph, Patterson, Kathryn, Dutt, Aparna, Ng, Yi Min, Thomas, Huw D, Wilson, Laura, McCullough, Benjamin, Jones, Dominic, Maan, Arussa, Banks, Peter, McCracken, Stuart R, Gaughan, Luke, Robson, Craig N, Coffey, Kelly |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261174/ https://www.ncbi.nlm.nih.gov/pubmed/32324216 http://dx.doi.org/10.1093/nar/gkaa271 |
Ejemplares similares
-
A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities
por: Kounatidou, Evangelia, et al.
Publicado: (2019) -
Regulation of the androgen receptor by SET9-mediated methylation
por: Gaughan, Luke, et al.
Publicado: (2011) -
The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer
por: Wade, Mark A., et al.
Publicado: (2015) -
The interaction between the Spt6-tSH2 domain and Rpb1 affects multiple functions of RNA Polymerase II
por: Connell, Zaily, et al.
Publicado: (2021) -
KDM4B is a Master Regulator of the Estrogen Receptor Signalling Cascade
por: Gaughan, Luke, et al.
Publicado: (2013)